Cargando…

Humoral immunity against Covid-19 six months after the Pfizer BNT162b2 vaccine in hemodialysis patients: data from five dialysis units. Is there a protective role for hemodiafiltration in the Covid-19 pandemic?

Detalles Bibliográficos
Autores principales:	Chuva, Teresa, Santos, Teresa, Gonçalves, Francisco, Costa, Luísa, Alves, Elisabete, Neves, Inês, Paiva, Ana, Carvalho, Berta, Sousa, Tânia, Ramalheiro, António, Maximino, José, Vila-Afonso, Luísa, Vidal Pinheiro, Luís, Corrêa, Otília, Loureiro, Alfredo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9171482/ https://www.ncbi.nlm.nih.gov/pubmed/35670962 http://dx.doi.org/10.1007/s40620-022-01350-9

Ejemplares similares

Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
por: Shashar, Moshe, et al.
Publicado: (2022)

Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers
por: Salvagno, Gian Luca, et al.
Publicado: (2021)

Neutrophilic urticarial dermatosis following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccination
por: Matsubara, Akihiro, et al.
Publicado: (2021)

POS-928 EFFICACY OF THE PFIZER/ BNT162b2 COVID-19 VACCINE IN PERITONEAL DIALYSIS PATIENTS
por: BEIRÃO, B., et al.
Publicado: (2022)

Pfizer BNT 162b2 COVID-19 vaccine–induced fulminant myopericarditis: A case study
por: Montarello, Natalie L., et al.
Publicado: (2023)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study
por: Achiron, Anat, et al.
Publicado: (2021)

Cerebral Venous Sinus Thrombosis After Pfizer-BioNTech COVID-19 (BNT162b2) Vaccination
por: Cheng, Newman
Publicado: (2021)

Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine
por: Akiyama, Hiroaki, et al.
Publicado: (2021)

Vulvar Aphthous Ulcer in an Adolescent After Pfizer-BioNTech (BNT162b2) COVID-19 Vaccination
por: Wojcicki, Anna V., et al.
Publicado: (2022)

Pfizer-BioNTech COVID-19 Vaccine (BNT162b2) Side Effects: A Systematic Review
por: Dighriri, Ibrahim M, et al.
Publicado: (2022)

Pulmonary Embolism after Vaccination with the COVID-19 Vaccine (Pfizer, BNT162b2): A Case Report
por: Kim, Eun-Ju, et al.
Publicado: (2023)

Previous COVID-19 infection, but not Long-COVID, is associated with increased adverse events following BNT162b2/Pfizer vaccination
por: Raw, Rachael Kathleen, et al.
Publicado: (2021)

Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis
por: Jahn, Michael, et al.
Publicado: (2021)

Decline of Humoral Responses 6 Months after Vaccination with BNT162b2 (Pfizer–BioNTech) in Patients on Hemodialysis
por: Jahn, Michael, et al.
Publicado: (2022)

Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community
por: Abukhalil, Abdallah Damin, et al.
Publicado: (2023)

Severe hyponatraemia with cerebral oedema after Pfizer BNT162b2 mRNA vaccination against COVID-19
por: Dharma, J.F.M., et al.
Publicado: (2023)

Tachycardia as an undescribed adverse effect to the Comirnaty© vaccine (BNT162b2 Pfizer-BioNTech Covid-19 vaccine): Description of 3 cases with a history of SARS-CoV-2 disease()
por: Marco García, M. Teresa, et al.
Publicado: (2022)

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
por: Cele, Sandile, et al.
Publicado: (2021)

Variation in the Humoral Immune Response Induced by the Administration of the BNT162b2 Pfizer/BioNTech Vaccine: A Systematic Review
por: Cortés-Sarabia, Karen, et al.
Publicado: (2022)

A Case of Idiopathic Thrombocytopenic Purpura After Booster Dose of BNT162b2 (Pfizer-Biontech) COVID-19 Vaccine
por: Malayala, Srikrishna V, et al.
Publicado: (2021)

Cerebellar and brainstem stroke possibly associated with booster dose of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine
por: Thomas, Michael George, et al.
Publicado: (2023)

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
por: Levin, Einav G., et al.
Publicado: (2021)

Humoral and Cellular Immune Response Elicited by the BNT162b2 COVID-19 Vaccine Booster in Elderly
por: Dalla Gasperina, Daniela, et al.
Publicado: (2023)

Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech)
por: Korth, Johannes, et al.
Publicado: (2021)

A racing heart post‐Pfizer/BioNTech BNT162b2
por: Teo, Hooi Khee, et al.
Publicado: (2022)

Stability testing of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine: a translational study in UK vaccination centres
por: Kudsiova, Laila, et al.
Publicado: (2021)

Recurrent erythema nodosum after the second dose of the Pfizer-BioNTech BNT162b2 COVID-19 messenger RNA vaccine
por: Wu, Xiaotian, et al.
Publicado: (2021)

Clinicopathological Characteristics of Inflammatory Myositis Induced by COVID-19 Vaccine (Pfizer-BioNTech BNT162b2): A Case Report
por: Kim, Ji Hyoun, et al.
Publicado: (2022)

Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) COVID-19 mRNA vaccines and hypersensitivity reactions
por: Haq, Hannah N., et al.
Publicado: (2022)

Acute adrenal insufficiency in a patient with panhypopituitarism after vaccination against COVID-19 (BNT162b2 Pfizer-BioNTech)
por: González López, Javier, et al.
Publicado: (2022)

Intracranial Hemorrhage After Pfizer-BioNTech (BNT162b2) mRNA COVID-19 Vaccination: A Case Report
por: Yangi, Kivanc, et al.
Publicado: (2023)

Adverse Events Following the BNT162b2 mRNA COVID-19 Vaccine (Pfizer-BioNTech) in Aotearoa New Zealand
por: Walton, Muireann, et al.
Publicado: (2023)

The Humoral Response of Patients With Cancer to Breakthrough COVID-19 Infection or the Fourth BNT162b2 Vaccine Dose
por: Cohen, Idan, et al.
Publicado: (2023)

BNT162b2 vaccine for prevention of COVID-19
Publicado: (2021)

Prior COVID-19 infection is associated with increased Adverse Events (AEs) after the first, but not the second, dose of the BNT162b2/Pfizer vaccine
por: Raw, Rachael K., et al.
Publicado: (2022)

Systemic capillary leak syndrome (SCLS) after receiving BNT162b2 mRNA COVID-19 (Pfizer-BioNTech) vaccine
por: Inoue, Masatoshi, et al.
Publicado: (2022)

Assessment of Immediate Allergic Reactions After Immunization With the Pfizer BNT162b2 Vaccine Using Intradermal Skin Testing With the COVID-19 Vaccines
por: Shavit, Ronen, et al.
Publicado: (2022)

Safety of mRNA BNT162b2 COVID-19 (Pfizer-BioNtech) vaccine in children aged 5-11 years: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

Increased adverse events following third dose of BNT162b2/Pfizer vaccine in those with previous COVID-19, but not with concurrent influenza vaccine
por: Raw, Rachael K., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lltpru54rko5pqtqbmftqhos0m